A multi-center phase II clinical trial (NCT03196830) also concluded that the combination of anti-PD-1 antibody showed an enhancement effect on CD30 CAR-T therapy in R/R CD30-positive lymphoma patients with minimal toxicities (112). The gene discussed is TNFRSF8; the disease is lymphoma.